Neurothera Labs (TSXV:NTLX) Cyclically Adjusted PS Ratio: (As of Aug. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSXV:NTLX Neurothera Labs Inc TSXV:NTLX
31 GF Score
Price C$0.33
! 2 Warning Signs
View Full Analysis

What is Neurothera Labs Cyclically Adjusted PS Ratio?

Neurothera Labs does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Neurothera Labs  (TSXV:NTLX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Neurothera Labs Cyclically Adjusted PS Ratio Related Terms


Neurothera Labs Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Neurothera Labs's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurothera Labs Cyclically Adjusted PS Ratio Chart

Neurothera Labs Annual Data
Trend Jan21 Jan22 Jan23 Jan24 Jan25
Cyclically Adjusted PS Ratio
0.00 0.00 0.00 0.00 0.00

Neurothera Labs Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Dec25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSXV:NTLX vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, Neurothera Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurothera Labs Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Neurothera Labs's Cyclically Adjusted PS Ratio falls into.


TSXV:NTLX
31GF Score
Neurothera Labs Inc TSXV:NTLX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurothera Labs Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Neurothera Labs does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Neurothera Labs Business Description

Address 325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
31GF Score

Get the complete analysis for TSXV:NTLX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.33
Price